InnoPharmax マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Weihua Hao

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Would Shareholders Who Purchased InnoPharmax's (GTSM:4172) Stock Five Years Be Happy With The Share price Today?

Feb 22

We Think InnoPharmax (GTSM:4172) Can Afford To Drive Business Growth

Dec 04

CEO（最高経営責任者

Weihua Hao

no data

在職期間

Weihua Hao is Manager of InnoPharmax Inc.

InnoPharmax マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

InnoPharmax Inc., Annual General Meeting, May 27, 2021

Recent updates

New major risk - Share price stability

New minor risk - Share price stability

Full year 2023 earnings released: NT$0.77 loss per share (vs NT$1.19 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: NT$0.33 loss per share (vs NT$0.56 loss in 1H 2022)

New minor risk - Shareholder dilution

Full year 2022 earnings released: NT$1.19 loss per share (vs NT$1.08 loss in FY 2021)

First half 2022 earnings released: NT$0.56 loss per share (vs NT$0.48 loss in 1H 2021)

Full year 2021 earnings released: NT$1.08 loss per share (vs NT$0.57 loss in FY 2020)

Full year 2020 earnings released: NT$0.57 loss per share (vs NT$1.24 loss in FY 2019)

New 90-day high: NT$19.05

InnoPharmax Inc., Annual General Meeting, May 27, 2021

Would Shareholders Who Purchased InnoPharmax's (GTSM:4172) Stock Five Years Be Happy With The Share price Today?

New 90-day low: NT$14.55

New 90-day low: NT$16.55

We Think InnoPharmax (GTSM:4172) Can Afford To Drive Business Growth

New 90-day low: NT$17.05

New 90-day low: NT$17.50

New 90-day low: NT$22.00

New 90-day low: NT$22.80

First half earnings released

CEO（最高経営責任者

在職期間

InnoPharmax マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

InnoPharmax Inc., Annual General Meeting, May 27, 2021

Recent updates

New major risk - Share price stability

New minor risk - Share price stability

Full year 2023 earnings released: NT$0.77 loss per share (vs NT$1.19 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: NT$0.33 loss per share (vs NT$0.56 loss in 1H 2022)

New minor risk - Shareholder dilution

Full year 2022 earnings released: NT$1.19 loss per share (vs NT$1.08 loss in FY 2021)

First half 2022 earnings released: NT$0.56 loss per share (vs NT$0.48 loss in 1H 2021)

Full year 2021 earnings released: NT$1.08 loss per share (vs NT$0.57 loss in FY 2020)

Full year 2020 earnings released: NT$0.57 loss per share (vs NT$1.24 loss in FY 2019)

New 90-day high: NT$19.05

InnoPharmax Inc., Annual General Meeting, May 27, 2021

Would Shareholders Who Purchased InnoPharmax's (GTSM:4172) Stock Five Years Be Happy With The Share price Today?

New 90-day low: NT$14.55

New 90-day low: NT$16.55

We Think InnoPharmax (GTSM:4172) Can Afford To Drive Business Growth

New 90-day low: NT$17.05

New 90-day low: NT$17.50

New 90-day low: NT$22.00

New 90-day low: NT$22.80

First half earnings released

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04